Cargando…

Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects

Heart failure (HF) with reduced ejection fraction is common following acute myocardial infarction (MI), and active medical management can have a profound impact on prognosis. Reviewing relevant clinical trials, we focus on the pharmacological management of left ventricular systolic dysfunction (LVSD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abel, Alexandra A I, Clark, Andrew L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593493/ https://www.ncbi.nlm.nih.gov/pubmed/34795500 http://dx.doi.org/10.2147/IJGM.S294896

Ejemplares similares

Targeting heart failure with preserved ejection fraction: current status and future prospects
por: Kanwar, Manreet, et al.
Publicado: (2016)

Heart failure with preserved ejection fraction: current status and challenges for the future
por: van der Velden, J., et al.
Publicado: (2016)

Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
por: Chaudhary, Ammar G., et al.
Publicado: (2021)

Pharmacological Targets in Chronic Heart Failure with Reduced Ejection Fraction
por: Moloce, Maria-Angela, et al.
Publicado: (2022)

Long-term impact of postconditioning on infarct size and left ventricular ejection fraction in patients with ST-elevation myocardial infarction
por: Sörensson, Peder, et al.
Publicado: (2013)

Assessment of Clopidogrel on the Left Ventricular Ejection Fraction in Acute Myocardial Infarction
por: Khosravi, Pejman, et al.
Publicado: (2010)

Myocardial Contraction Fraction is Superior to Ejection Fraction in Predicting Functional Capacity in Patients with Heart Failure with Reduced Ejection Fraction
por: Abdellatif, Yasser A., et al.
Publicado: (2022)

Prognostic Impact of Non-Cardiac Comorbidities on Long-Term Prognosis in Patients with Reduced and Preserved Ejection Fraction following Acute Myocardial Infarction
por: Savic, Lidija, et al.
Publicado: (2023)

Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
por: Girerd, Nicolas, et al.
Publicado: (2022)

Predominant subtype of heart failure after acute myocardial infarction is heart failure with non‐reduced ejection fraction
por: Kamon, Daisuke, et al.
Publicado: (2020)

Acute heart failure with mildly reduced ejection fraction and myocardial infarction: a multi-institutional cohort study
por: Lin, Ming-Shyan, et al.
Publicado: (2023)

Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction
por: Nauta, J. F., et al.
Publicado: (2021)

Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions
por: Wohlfahrt, Peter, et al.
Publicado: (2022)

Myocardial Surgical Revascularization in Patients with Reduced Left Ventricular Ejection Fraction
por: Kadric, Nedzad, et al.
Publicado: (2022)

Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction
por: Herring, Neil, et al.
Publicado: (2019)

Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
por: Egbuche, Obiora, et al.
Publicado: (2020)

Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
por: D'Amario, Domenico, et al.
Publicado: (2023)

Corrected thrombolysis in myocardial infarction frame count and ejection fraction in patients undergoing primary percutaneous coronary intervention for myocardial infarction
por: Vakili, Hossein, et al.
Publicado: (2013)

Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
por: Wilton, Stephen B., et al.
Publicado: (2021)

Heart Failure with Preserved Left Ventricular Ejection Fraction in Patients with Acute Myocardial Infarction
por: Antonelli, Lucas, et al.
Publicado: (2015)

Association of Plasma Methylglyoxal Increase after Myocardial Infarction and the Left Ventricular Ejection Fraction
por: Heber, Stefan, et al.
Publicado: (2022)

Myocardial infarction with a preserved ejection fraction—the impaired function of the cardio-renal baroreflex
por: Pickny, Lisa, et al.
Publicado: (2023)

Heart failure with preserved ejection fraction: present status and future directions
por: Yoon, Somy, et al.
Publicado: (2019)

Vascular Dysfunction Predicts Future Deterioration of Left Ventricular Ejection Fraction in Patients with Heart Failure with Mildly Reduced Ejection Fraction
por: Kishimoto, Shinji, et al.
Publicado: (2021)

Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction
por: Wang, Tracy Y., et al.
Publicado: (2016)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction
por: Nowosielski, Martha, et al.
Publicado: (2009)

Ejection Fraction and Mortality Rate of Patients with Isolated Acute Inferior Myocardial Infarction Reperfused by Streptokinase
por: Beiraghdar, Mozhdeh, et al.
Publicado: (2011)

Relationship between left ventricular ejection fraction and depression following myocardial infarction: an original article
por: Bagherian-Sararoudi, Reza, et al.
Publicado: (2013)

Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Predictive factors of left ventricular ejection fraction improvement after myocardial infarction treated invasively
por: Lazar, Monika, et al.
Publicado: (2023)

Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
por: Kessler, Elise L., et al.
Publicado: (2020)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature
por: Techorueangwiwat, Chol, et al.
Publicado: (2021)

Rapid predictors for the occurrence of reduced left ventricular ejection fraction between LAD and non-LAD related ST-elevation myocardial infarction
por: Chen, Zhang-Wei, et al.
Publicado: (2016)

Evaluation of cardiometabolic risk markers linked to reduced left ventricular ejection fraction (LVEF) in patients with ST-elevation myocardial infarction (STEMI)
por: Mahdavi-Roshan, Marjan, et al.
Publicado: (2022)

Myocardial expression of somatotropic axis, adrenergic signalling, and calcium handling genes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction
por: D'Assante, Roberta, et al.
Publicado: (2021)

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2021)

A practical approach to the guideline‐directed pharmacological treatment of heart failure with reduced ejection fraction
por: Abdin, Amr, et al.
Publicado: (2022)

Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review
por: Sanromán Guerrero, María Ascensión, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b0f0267cqs885572plpja57mie